Zevra Therapeutics, Inc. (ZVRA) · Nov 3, 2026 · Earnings
Beat — Diluted EPS $0.26 vs ~$0.14 consensus; revenue $37.8M vs ~$37.1M
Zevra’s Q3 earnings modestly beat expectations as MIPLYFFA revenue climbed and celiprolol enrollment advanced, with cash supporting 2027 milestones.
Zevra is a commercial-stage rare-disease company using MIPLYFFA as its revenue base while funding celiprolol and broader geographic expansion. The quarter lands modestly ahead of published expectations: consensus was roughly $37.1 million of revenue and $0.14–$0.16 of EPS.
| Q3 2026 | Q3 2025 | Consensus | |
|---|---|---|---|
| Revenue, net (Financial Highlights) | $37.8M (+44.9%) | $26.1M | ~$37.1M |
| MIPLYFFA net revenue (Financial Highlights) | $34.0M | — | — |
| Diluted EPS (Income Statement) | $0.26 | $(0.01) | ~$0.14 |
| Cash, equivalents and investments (Cash Position) | $270.9M | — | — |
The commercial engine is improving, but the headline revenue beat is narrow. MIPLYFFA generated $34.0 million, up from $30.2 million in Q2, while global EAP reimbursements fell to $3.6 million from $9.0 million in the prior quarter. That mix shift is constructive because product revenue is becoming more important, but it also explains why total revenue declined sequentially despite stronger underlying MIPLYFFA sales. The company said, “Revenue, Net: $37.8million for Q3 2026, which includes $34.0million of MIPLYFFA net revenue, $0.2million of OLPRUVA net revenue, and $3.6million in net reimbursements from our global EAP.”
The EPS beat overstates the quality of the operating upside. Operating income improved to $11.6 million from $4.1 million as revenue grew, but reported profit also benefited from a $5.1 million noncash gain tied to warrant and CVR liabilities, versus a $5.5 million noncash expense last year. R&D rose to $4.9 million as Zevra invested in arimoclomol and celiprolol, so the business is profitable in the quarter while still increasing development spending. The filing states, “In Q3 2026, the Company recognized $5.1million in noncash income due to fair value adjustments related to warrant and contingent value rights (CVR) liability compared to $(5.5) million of noncash expense in Q3 2025.”
Pipeline execution moved forward, but the major clinical proof point is still ahead. Celiprolol enrollment increased by six patients to 72, with four confirmed events, and FDA discussions on a potential submission strategy add regulatory momentum. Separately, the planned Q1 2027 MIPLYFFA sNDA could expand the addressable population to infants under 24 months. These are meaningful advances to the story, but neither is yet a regulatory approval or clinical efficacy readout. The company said, “Company anticipates filing sNDA in Q1 2027.” 〔0〕
Liquidity reduces near-term funding pressure. Cash, cash equivalents and investments totaled $270.9 million, and the balance sheet showed no long-term debt at September 30, 2026. That gives Zevra room to pursue the sNDA, European access efforts and celiprolol development without the filing signaling an immediate financing need. The company reported, “Cash, cash equivalents and investments were $270.9million as of September 30, 2026.”
Bottom line: This is a modest execution beat that strengthens Zevra’s commercial-to-pipeline transition, chiefly because MIPLYFFA sales are carrying more of the business. The upside is real but limited: the revenue beat is small, and the large EPS outperformance partly reflects noncash accounting gains rather than a sudden step-up in core economics.
MIPLYFFA sNDA filing, Q1 2027
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!